// App-Quantinova.ai

EP1046 : ASSESSING TIME TO DETERIORATION IN HRQOL IN PATIENTS WITH MULTIPLE MYELOMA USING VENETOCLAX IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE COMPARED WITH PATIENTS USING BORTEZOMIB AND DEXAMETHASONE

Researchers

Presenter

  • Philippe Moreau

Principal Investigators

  • Rakesh Popat

  • Shaji Kumar

  • Michele Cavo

  • Javier de la Rubia

  • Vania Hungria

  • Hans Salwender

  • Inho Kim

  • Simon Harrison

  • Jalaluddin Muhammad

  • Amal Melhem Bertrandt

  • Robert F Cornell

  • Sudeep Karve

  • Kristina Fitzgerald

  • Rajesh Kamalakar

  • Jacob Devine

Medical Centers

  • Genentech Inc., San Francisco, United States

  • University Hospital La Fe, Valencia, Spain

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • CHU Nantes, Nantes, France

  • Clinica Sao Peregrino, Sao Paulo, Brazil

  • Asklepios Klinik St. Georg, Hamburg, Germany

  • AbbVie,Mettawa,United States

  • Japanese Red Cross Medical Center, Tokyo, Japan

  • Seragnoli Institute of Hematology, Bologna, Italy.

  • Mayo Clinic, Rochester, United States

Locations

  • United States

  • Spain

  • Australia

  • France

  • Brazil

  • Germany

  • United Kingdom

  • Japan

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bortezomib

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01794520

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved